Chu Yu-Waye, Chief Medical Officer of CytomX Therapeutics ($CTMX), sold shares once on the open market in the last 365 days for a total of $2,411. His most recent sale occurred on March 18, 2025. These sales rank 11,481st among 11,678 insiders in the database by amount sold, well below the average of $8.6 million per insider and 6.4 transactions. Chu Yu-Waye made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 17, 2026 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 21279 | $6.42 | 189,446.0000 | 169,435,395 | 10.10% | 0.01% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 169,435,395 | 9999.99% | 0.18% |
| Feb. 2, 2026 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 75000 | $0.00 | 210,725.0000 | 169,435,395 | 55.26% | 0.04% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Performance Stock Units (PSUs) | 43750 | $0.00 | 43,750.0000 | 80,099,889 | 9999.99% | 0.05% |
| Sept. 26, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 87500 | $0.00 | 87,500.0000 | 80,099,889 | 9999.99% | 0.11% |
| March 18, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 4025 | $0.60 | 135,725.0000 | 80,099,889 | 2.88% | 0.01% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 57500 | $0.00 | 139,750.0000 | 0 | 69.91% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 115000 | $0.00 | 115,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 56000 | $0.00 | 82,250.0000 | 0 | 213.33% | 0.00% |
| Feb. 4, 2025 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 238000 | $0.00 | 238,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Common Stock | 26250 | $0.00 | 26,250.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 122500 | $0.00 | 122,500.0000 | 0 | 9999.99% | 0.00% |
| Jan. 18, 2024 | CytomX Therapeutics, Inc. | $CTMX | Chu Yu-Waye | Chief Medical Officer | A | Performance Stock Units (PSUs) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| April 18, 2023 | FATE THERAPEUTICS INC | $FATE | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 215 | $6.52 | 142,993.0000 | 0 | 0.15% | 0.00% |
| April 18, 2023 | FATE THERAPEUTICS INC | $FATE | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 2317 | $6.58 | 140,676.0000 | 0 | 1.62% | 0.00% |
| Feb. 6, 2023 | FATE THERAPEUTICS INC | $FATE | Chu Yu-Waye | Chief Medical Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 10, 2023 | FATE THERAPEUTICS INC | $FATE | Chu Yu-Waye | Chief Medical Officer | S | Common Stock | 7825 | $5.24 | 143,208.0000 | 0 | 5.18% | 0.00% |